New drug aims to stop immune attack after stem cell transplants
NCT ID NCT07246031
First seen Nov 24, 2025 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study tests a new drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a half-matched donor. aGVHD is a serious condition where donor immune cells attack the patient's body. The trial includes 50 adults with blood cancers who will receive BPC2001 along with standard care. The goal is to see if the drug reduces severe aGVHD and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.